A new report available from BCC Research projects a compound annual growth rate (CAGR) of 14.3% for the respiratory drug delivery technologies market, meaning that the global market would approximately double to $44 billion by 2016. According to the report, the market, including MDIs, DPIs, and other devices, was $19.6 billion in 2010 would be about $22.5 billion for 2011. The report is titled, “Pulmonary Drug Delivery Systems: Technologies and Global Markets.”
The market for dry powder inhalers, the report says, should increase from $6.6 billion in 2010 to $13.4 billion by 2016 at a CAGR of 12.3%, fueled by technological advances in formulation. For MDIs, the analyst projects a CAGR of 15.7% and an increase from $12.5 billion in 2010 to almost $30 billion by 2016.
According to the table of contents, the report identifies the following companies as “key companies”: 3M, Akela, Alexza, Alkermes, AlphaRx, AOP Orphan Pharmaceuticals, APT Pharmaceuticals, Aradigm, AstraZeneca, Axentis Pharma, Consort Medical [Bespak], Daiichi Sankyo, Dey, Gilead, GSK, Graceway Pharmaceuticals [recently purchased by Galderma], Hovione, Inspire [acquired by Merck], MannKind Corporation, MAP Pharmaceuticals, Merck, MicroDose Therapeutx, MPEX, Nektar, Next Safety, Novartis, Oriel, Pearl, Pharmaxis, Pulmatrix, Respirics, Savara, SkyePharma, Sunovion, Synairgen, Teva, Theravance, United Therapeutics, and Vectura.
Read the report highlights.
View the table of contents.
